A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradication of minimal residual disease.